Two Sigma Advisers’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,200
| Closed | -$508K | – | 2540 |
|
|
2025
Q2 | $508K | Buy |
+4,200
| New | +$473K | ﹤0.01% | 1746 |
|
|
2025
Q1 | – | Sell |
-4,600
| Closed | -$448K | – | 2528 |
|
|
2024
Q4 | $448K | Buy |
4,600
+900
| +24% | +$96K | ﹤0.01% | 1817 |
|
|
2024
Q3 | $426K | Sell |
3,700
-200
| -5% | -$22.7K | ﹤0.01% | 1768 |
|
|
2024
Q2 | $415K | Buy |
+3,900
| New | +$391K | ﹤0.01% | 1960 |
|
|
2023
Q4 | – | Sell |
-8,600
| Closed | -$876K | – | 2598 |
|
|
2023
Q3 | $876K | Sell |
8,600
-15,800
| -65% | -$1.6M | ﹤0.01% | 1579 |
|
|
2023
Q2 | $2.46M | Sell |
24,400
-508,000
| -95% | -$50.8M | 0.01% | 1087 |
|
|
2023
Q1 | $49M | Sell |
532,400
-1,074,100
| -67% | -$93.8M | 0.13% | 169 |
|
|
2022
Q4 | $146M | Sell |
1,606,500
-729,300
| -31% | -$61.4M | 0.41% | 51 |
|
|
2022
Q3 | $178M | Sell |
2,335,800
-237,400
| -9% | -$19.7M | 0.51% | 35 |
|
|
2022
Q2 | $218M | Sell |
2,573,200
-363,500
| -12% | -$31.9M | 0.62% | 28 |
|
|
2022
Q1 | $258M | Buy |
2,936,700
+67,000
| +2% | +$5.8M | 0.69% | 29 |
|
|
2021
Q4 | $251M | Buy |
2,869,700
+772,900
| +37% | +$64.2M | 0.63% | 40 |
|
|
2021
Q3 | $171M | Buy |
2,096,800
+203,700
| +11% | +$18.3M | 0.44% | 57 |
|
|
2021
Q2 | $173M | Buy |
+1,893,100
| New | +$169M | 0.46% | 52 |
|
|
2020
Q2 | – | Sell |
-39,300
| Closed | -$3.24M | – | 2571 |
|
|
2020
Q1 | $3.24M | Buy |
+39,300
| New | +$3.51M | 0.01% | 876 |
|
|
2019
Q4 | – | Sell |
-52,700
| Closed | -$4.58M | – | 2439 |
|
|
2019
Q3 | $4.58M | Buy |
52,700
+43,000
| +443% | +$3.86M | 0.01% | 795 |
|
|
2019
Q2 | $886K | Buy |
+9,700
| New | +$821K | ﹤0.01% | 1576 |
|
|
2018
Q4 | – | Sell |
-6,473
| Closed | -$500K | – | 2422 |
|
|
2018
Q3 | $500K | Sell |
6,473
-203,335
| -97% | -$15M | ﹤0.01% | 1799 |
|
|
2018
Q2 | $14.2M | Buy |
209,808
+184,475
| +728% | +$12.7M | 0.04% | 480 |
|
|
2018
Q1 | $1.83M | Buy |
+25,333
| New | +$1.93M | 0.01% | 1283 |
|
|
2017
Q1 | – | Sell |
-7,589
| Closed | -$495K | – | 2428 |
|
|
2016
Q4 | $495K | Buy |
+7,589
| New | +$492K | ﹤0.01% | 1882 |
|
|
2015
Q3 | – | Sell |
-2,775
| Closed | -$245K | – | 1921 |
|
|
2015
Q2 | $245K | Buy |
+2,775
| New | +$255K | ﹤0.01% | 1691 |
|
|
2013
Q3 | – | Sell |
-123,851
| Closed | -$7.85M | – | 2300 |
|
|
2013
Q2 | $7.85M | Buy |
+123,851
| New | +$8.06M | 0.11% | 173 |
|
Other funds holding NVS
Two Sigma Advisers's NVS Position: Q3 2025 in Review
Two Sigma Advisers sold out of Novartis (NVS) in Q3 2025, closing a stake of 4,200 shares — an estimated $508K sold.
Two Sigma Advisers first reported a position in NVS in Q2 2013 and held it in 23 quarters. The position peaked at $258M in Q1 2022. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.
- Two Sigma Advisers reported no remaining Novartis position as of Q3 2025 after selling out during the quarter.
- Two Sigma Advisers sold 4,200 Novartis shares in Q3 2025, an estimated $508K.
- Two Sigma Advisers first reported a position in Novartis in Q2 2013 and held it in 23 quarters.
- Two Sigma Advisers's Novartis position peaked at $258M in Q1 2022.
- 1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.
Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.